Non-nicotinic therapies for smoking cessation

Annual Review of Pharmacology and Toxicology

Volumn 47, Issue , 2007, Pages 541-564

  Siu, Eric C K ^a   Tyndale, Rachel F ^a  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Bupropion; CYP2A6; Nicotine metabolism; Rimonabant; Vaccines; Varenicline

Indexed keywords

ALKALOID DERIVATIVE; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CHOLERA TOXIN B SUBUNIT; CHOLINERGIC RECEPTOR; CLONIDINE; CYTISINE; CYTOCHROME P450 2A6; DOPAMINE; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; ENDOCANNABINOID; MECAMYLAMINE; MONOAMINE OXIDASE INHIBITOR; NICOTINE; NICOTINE VACCINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT; NORTRIPTYLINE; PLACEBO; RIMONABANT; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VARENICLINE;

ABNORMAL DREAMING; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG INDICATION; DRUG WITHDRAWAL; FLU LIKE SYNDROME; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEALTH HAZARD; HUMAN; INJECTION SITE REACTION; INSOMNIA; MYALGIA; NAUSEA; NICOTINE REPLACEMENT THERAPY; NONHUMAN; ORTHOSTATIC HYPOTENSION; PREVENTIVE MEDICINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK REDUCTION; SEDATION; SIDE EFFECT; SMOKING CESSATION; TOBACCO DEPENDENCE; UPPER RESPIRATORY TRACT INFECTION; VOMITING; XEROSTOMIA;

BENZAZEPINES; BUPROPION; DOPAMINE UPTAKE INHIBITORS; DRUGS, INVESTIGATIONAL; HUMANS; NICOTINE; NICOTINIC AGONISTS; QUINOXALINES; SMOKING CESSATION; TOBACCO USE DISORDER;

EID: 33847047118     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.47.120505.105354     Document Type: Review

References (183)

1. Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R. 2000. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ 321:323-29
2. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. 2005. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann. Intern. Med. 142:233-39
3. Henningfield JE, Keenan RM. 1993. Nicotine delivery kinetics and abuse liability. J. Consult. Clin. Psychol. 61:743-50
4. Maes HH, Sullivan PF, Bulik CM, Neale MC, Prescott CA, et al. 2004. A twin study of genetic and environmental influences n tobacco initiation, regular tobacco use and nicotine dependence. Psychol. Med. 34:1251-61
5. Benowitz NL. 1988. Drug therapy. Pharmacologic aspects of cigarette smoking and nicotine addition. N. Engl. J. Med. 319:1318-30
6. Scherer G. 1999. Smoking behavior and compensation: a review of the literature. Psychopharmacology 145:1-20
7. Balfour DJ. 2004. The neurobiology of tobacco dependence: a preclinical perspective on the role of the dopamine projections to the nucleus accumbens [corrected]. Nicotine Tob. Res. 6:899-912
8. James JR, Villanueva HF, Johnson JH, Arezo S, Rosecrans JA. 1994. Evidence that nicotine can acutely desensitize central nicotinic acetylcholinergic receptors. Psychopharmacology 114:456-62
9. Robinson SE, James JR, Lapp LN, Vann RE, Gross DF, et al. 2006. Evidence of cellular nicotinic receptor desensitization in rats exhibiting nicotine-induced acute tolerance. Psychopharmacology 184:306-13
10. Gentry CL, Lukas RJ. 2002. Regulation of nicotinic acetylcholine receptor numbers and function by chronic nicotine exposure. Curr. Drug Targets CNS Neurol. Disord. 1:359-85
11. Breese CR, Marks MJ, Logel J, Adams CE, Sullivan B, et al. 1997. Effect of smoking history on [3H]nicotine binding in human postmortem brain. J. Pharmacol. Exp. Ther. 282:7-13
12. Marks MJ, Romm E, Gaffney DK, Collins AC. 1986. Nicotine-induced tolerance and receptor changes in four mouse strains. J. Pharmacol. Exp. Ther. 237:809-19
13. Marks MJ, Stitzel JA, Collins AC. 1986. Dose-response analysis of nicotine tolerance and receptor changes in two inbred mouse strains. J. Pharmacol. Exp. Ther. 239:358-64
14. Perry DC, Davila-Garcia MI, Stockmeier CA, Kellar KJ. 1999. Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies. J. Pharmacol. Exp. Ther. 289:1545-52
15. Nguyen HN, Rasmussen BA, Perry DC. 2004. Binding and functional activity of nicotinic cholinergic receptors in selected rat brain regions are increased following long-term but not short-term nicotine treatment. J. Neurochem. 90:40-49
16. Parker SL, Fu Y, McAllen K, Luo J, McIntosh JM, et al. 2004. Up-regulation of brain nicotinic acetylcholine receptors in the rat during long-term self-administration of nicotine: disproportionate increase of the alpha6 subunit. Mol. Pharmacol. 65:611-22
17. Henningfield JE, Goldberg SR. 1988. Pharmacologic determinants of tobacco self-administration by humans. Pharmacol. Biochem. Behav. 30:221-26
18. Russell MA, Feyerabend C. 1978. Cigarette smoking: a dependence on high-nicotine boli. Drug. Metab. Rev. 8:29-57
19. Le Houezec J. 2003. Role of nicotine pharmacokinetics in nicotine addiction and nicotine replacement therapy: a review. Int. J. Tuberc. Lung. Dis. 7:811-19
20. Stead L, Lancaster T. 2005. Nicotine replacement therapy for smoking cessation: Cochrane systematic review. Int. J. Epidemiol. 34:1001-2; discussion 2, 3
21. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. 2004. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst. Rev. 3:CD000146
22. Frishman WH, Mitta W, Kupersmith A, Ky T. 2006. Nicotine and non-nicotine smoking cessation pharmacotherapies. Cardiol. Rev. 14:57-73
23. Henningfield JE, Fant RV, Buchhalter AR, Stitzer ML. 2005. Pharmacotherapy for nicotine dependence. CA Cancer J. Clin. 55:281-99; quiz 322-23, 25
24. Mitrouska I, Bouloukaki I, Siafakas NM. 2006. Pharmacological approaches to smoking cessation. Pulm. Pharmacol. Ther. In press
25. Paperwalla KN, Levin TT, Weiner J, Saravay SM. 2004. Smoking and depression. Med. Clin. North Am. 88:1483-94, x-xi
26. Quattrocki E, Baird A, Yurgelun-Todd D. 2000. Biological aspects of the link between smoking and depression. Harv. Rev. Psychiatry 8:99-110
27. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, et al. 1999. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N. Engl. J. Med. 340:685-91
28. Durcan MJ, Deener G, White J, Johnston JA, Gonzales D, et al. 2002. The effect of bupropion sustained-release on cigarette craving after smoking cessation. Clin. Ther. 24:540-51
29. Shiffman S, Johnston JA, Khayrallah M, Elash CA, Gwaltney CJ, et al. 2000. The effect of bupropion on nicotine craving and withdrawal. Psychopharmacology 148:33-40
30. Tashkin D, Kanner R, Bailey W, Buist S, Anderson P, et al. 2001. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 357:1571-75
31. Learned-Coughlin SM, Bergstrom M, Savitcheva I, Ascher J, Schmith VD, Langstrom B. 2003. In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol. Psychiatry 54:800-5
32. Argyelan M, Szabo Z, Kanyo B, Tanacs A, Kovacs Z, et al. 2005. Dopamine transporter availability in medication free and in bupropion treated depression: a 99mTc-TRODAT-1 SPECT study. J. Affect Disord. 89:115-23
33. Cooper BR, Wang CM, Cox RF, Norton R, Shea V, Ferris RM. 1994. Evidence that the acute behavioral and electrophysiological effects of bupropion (Wellbutrin) are mediated by a noradrenergic mechanism. Neuropsychopharmacology 11:133-41
34. Vorel SR, Liu X, Hayes RJ, Spector JA, Gardner EL. 2001. Relapse to cocaine-seeking after hippocampal theta burst stimulation. Science 292:1175-78
35. Fryer JD, Lukas RJ. 1999. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J. Pharmacol. Exp. Ther. 288:88-92
36. Alkondon M, Albuquerque EX. 2005. Nicotinic receptor subtypes in rat hippocampal slices are differentially sensitive to desensitization and early in vivo functional up-regulation by nicotine and to block by bupropion. J. Pharmacol. Exp. Ther. 313:740-50
37. Slemmer JE, Martin BR, Damaj MI. 2000. Bupropion is a nicotinic antagonist. J. Pharmacol. Exp. Ther. 295:321-27
38. Damaj MI, Carroll FI, Eaton JB, Navarro HA, Blough BE, et al. 2004. Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol. Pharmacol. 66:675-82
39. Bondarev ML, Bondareva TS, Young R, Glennon RA. 2003. Behavioral and biochemical investigations of bupropion metabolites. Eur. J. Pharmacol. 474:85-93
40. Ahluwalia JS, Harris KJ, Catley D, Okuyemi KS, Mayo MS. 2002. Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial. JAMA 288:468-74
41. Aubin HJ, Lebargy F, Berlin I, Bidaut-Mazel C, Chemali-Hudry J, Lagrue G. 2004. Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo-controlled trial. Addiction 99:1206-18
42. Gold PB, Rubey RN, Harvey RT. 2002. Naturalistic, self-assignment comparative trial of bupropion SR, a nicotine patch, or both for smoking cessation treatment in primary care. Am. J. Addict. 11:315-31
43. Hays JT, Hurt RD, Rigotti NA, Niaura R, Gonzales D, et al. 2001. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation, a randomized, controlled trial. Ann. Intern. Med. 135:423-33
44. Hurt RD, Sachs DP, Glover ED, Offord KP, Johnston JA, et al. 1997. A comparison of sustained-release bupropion and placebo for smoking cessation. N. Engl. J. Med. 337:1195-202
45. Jamerson BD, Nides M, Jorenby DE, Donahue R, Garrett P, et al. 2001. Late-term smoking cessation despite initial failure: an evaluation of bupropion sustained release, nicotine patch, combination therapy, and placebo. Clin. Ther. 23:744-52
46. Swan GE, McAfee T, Curry SJ, Jack LM, Javitz H, et al. 2003. Effectiveness of bupropion sustained release for smoking cessation in a health care setting: a randomized trial. Arch. Intern. Med. 163:2337-44
47. Tonnesen P, Tonstad S, Hjalmarson A, Lebargy F, Van Spiegel PI, et al. 2003. A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation. J. Intern. Med. 254:184-92
48. Hughes J, Stead L, Lancaster T. 2004. Antidepressants for smoking cessation. Cochrane Database Syst. Rev 4:CD000031
49. Killen JD, Robinson TN, Ammerman S, Hayward C, Rogers J, et al. 2004. Randomized clinical trial of the efficacy of bupropion combined with nicotine patch in the treatment of adolescent smokers. J. Consult. Clin. Psychol. 72:729-35
50. Simon JA, Duncan C, Carmody TP, Hudes ES. 2004. Bupropion for smoking cessation: a randomized trial. Arch. Intern. Med. 164:1797-803
51. Boshier A, Wilton LV, Shakir SA. 2003. Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000. Eur. J. Clin. Pharmacol. 59:767-73
52. Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, et al. 2005. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J. Med. Chem. 48:3474-77
53. Papke RL, Heinemann SF. 1994. Partial agonist properties of cytisine on neuronal nicotinic receptors containing the beta 2 subunit. Mol. Pharmacol. 45:142-49
54. Bennodorf S, Kempe G, Scharfenberg G, Wendekamm R, Winkelvoss E. 1968. Results of the smoking-habit breaking using cytisin (Tabex). I. Dtsch. Gesundheitsw. 23:2092-96
55. Paun D, Franze J. 1968. Breaking the smoking habit using cytisin containing "Tabex" tablets. Dtsch. Gesundheitsw. 23:2088-91
56. McCallum SE, Collins AC, Paylor R, Marks MJ. 2006. Deletion of the beta 2 nicotinic acetylcholine receptor subunit alters development of tolerance to nicotine and eliminates receptor upregulation. Psychopharmacology 184:314-27
57. Tapper AR, McKinney SL, Nashmi R, Schwarz J, Deshpande P, et al. 2004. Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization. Science 306:1029-32
58. Walters CL, Cleck JN, Kuo YC, Blendy JA. 2005. Mu-opioid receptor and CREB activation are required for nicotine reward. Neuron 46:933-43
59. Oncken C, Watsky E, Reeves K, Anziano R. 2005. Smoking cessation with varenicline, a selective nicotinic receptor partial agonist: results from a phase 2 study. Presented at Proc. 11 Annu. Meet. Soc. Res. Nicotine Tobacco, Prague, Czech Rep.
60. Oncken C, Watsky E, Reeves K, Anziano R. 2005. Varenicline is efficacious and well tolerated in promoting smoking cessation: results from a 7-week, randomized, placebo- and bupropion-controlled trial. Presented at Proc. 11 Annu. Meet. Soc. Res. Nicotine Tobacco, Prague, Czech Rep.
61. Tonstad S, Hays JT, Jorenby DE, Reeves K, Billing CB, et al. 2005. Smoking cessation efficacy and safety of an alpha4beta2 nicotinic receptor partial agonist - results from varenicline in cessation therapy: optimizing results. Presented at Annu. Meet. Am. Heart Assoc., Chicago, IL
62. Cappelleri J, Baker CL, Bushmakin AG, Reeves KR. 2006. Effect of varenicline on reinforcing effects associated with smoking. Presented at Proc. 12 Annu. Meet. Soc. Res. Nicotine Tobacco, Orlando, FL
63. Reeves K, Watsky E, Williams K, Azoulay S, Billing B, Gong J. 2006. The safety of varenicline taken fro 52 weeks for smoking cessation. Presented at Proc. 12 Annu. Meet. Soc. Res. Nicotine Tobacco, Orlando, FL
64. Hieda Y, Keyler DE, Ennifar S, Fattom A, Pentel PR. 2000. Vaccination against nicotine during continued nicotine administration in rats: immunogenicity of the vaccine and effects on nicotine distribution to brain. Int. J. Immunopharmacol. 22:809-19
65. Pentel PR, Malin DH, Ennifar S, Hieda Y, Keyler DE, et al. 2000. A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol. Biochem. Behav. 65:191-98
66. Cerny T. 2005. Anti-nicotine vaccination: where are we? Recent Results Cancer Res. 166:167-75
67. Le Houezec J. 2005. Why a nicotine vaccine? Clin. Pharmacol. Ther. 78:453-55
68. LeSage MG, Keyler DE, Pentel PR. 2006. Current status of immunologic approaches to treating tobacco dependence: vaccines and nicotine-specific antibodies. Aaps J. 8:E65-75
69. Lindblom N, de Villiers SH, Kalayanov G, Gordon S, Johansson AM, Svensson TH. 2002. Active immunization against nicotine prevents reinstatement of nicotine-seeking behavior in rats. Respiration 69:254-60
70. Lesage MG, Keyler DE, Hieda Y, Collins G, Burroughs D, et al. 2006. Effects of a nicotine conjugate vaccine on the acquisition and maintenance of nicotine self-administration in rats. Psychopharmacology 184:409-16
71. Hatsukami DK, Rennard S, Jorenby D, Fiore M, Koopmeiners J, et al. 2005. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin. Pharmacol. Ther. 78:456-67
72. Lindblom N, de Villiers SH, Semenova S, Kalayanov G, Gordon S, et al. 2005. Active immunization against nicotine blocks the reward facilitating effects of nicotine and partially prevents nicotine withdrawal in the rat as measured by dopamine output in the nucleus accumbens, brain reward thresholds and somatic signs. Naunyn Schmiedebergs Arch. Pharmacol. 372:182-94
73. Maurer P, Jennings GT, Willers J, Rohner F, Lindman Y, et al. 2005. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur. J. Immunol. 35:2031-40
74. Pentel PR, Dufek MB, Roiko SA, LeSage MG, Ross CA, Keyler DE. 2006. Passive immunization with nicotine-specific monoclonal antibodies as an alternative to vaccination; pharmacokinetic evaluation in rats. Presented at Proc. 12 Annu. Meet. Soc. Res. Nicotine Tobacco, Orlando, FL
75. Malin DH, Lake JR, Lin A, Saldana M, Balch L, et al. 2001. Passive immunization against nicotine prevents nicotine alleviation of nicotine abstinence syndrome. Pharmacol. Biochem. Behav. 68:87-92
76. Malin DH, Newton MA, Goyarzu P, Vega SO, Torok NK, Pentel PR. 2006. Nicotine place preference conditioned in adolescent rats persists into adulthood and is preventable by immunization against nicotine. Presented at Proc. 12 Annu. Meet. Soc. Res. Nicotine Tobacco, Orlando, FL
77. Chen JP, Paredes W, LiJ, Smith D, Lowinson J, Gardner EL. 1990. Delta 9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis. Psychopharmacology 102:156-62
78. Tanda G, Pontieri FE, Di Chiara G. 1997. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 276:2048-50
79. French ED. 1997. delta9-Tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors. Neurosci. Lett. 226:159-62
80. Gonzalez S, Cascio MG, Fernandez-Ruiz J, Fezza F, Di Marzo V, Ramos JA. 2002. Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Res. 954:73-81
81. Shoemaker JL, Ruckle MB, Mayeux PR, Prather PL. 2005. Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors. J. Pharmacol. Exp. Ther. 315:828-38
82. Steffens M, Zentner J, Honegger J, Feuerstein TJ. 2005. Binding affinity and agonist activity of putative endogenous cannabinoids at the human neocortical CB1 receptor. Biochem. Pharmacol. 69:169-78
83. Cohen C, Perrault G, Voltz C, Steinberg R, Soubrie P. 2002. SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav. Pharmacol. 13:451-63
84. Cohen C, Perrault G, Griebel G, Soubrie P. 2005. Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716). Neuropsychopharmacology 30:145-55
85. Le Foll B, Goldberg SR. 2004. Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences. Neuroreport 15:2139-43
86. Castane A, Valjent E, Ledent C, Parmentier M, Maldonado R, Valverde O. 2002. Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence. Neuropharmacology 43:857-67
87. Cossu G, Ledent C, Fattore L, Imperato A, Bohme GA, et al. 2001. Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. Behav. Brain Res. 118:61-65
88. Anthenelli RM, Despres JP. 2004. Effects of rimonabant in the reduction of major cardiovascular risk factors. Results from the STRATUS-US trial (smoking cessation in smokers motivated to quit). Presented at Am. College Cardiol. 53rd Annu. Sci. Session, Rapid News Summaries, New Orleans, LA
89. Anthenelli RM. 2005. Rimonabant in smoking abstinence: the STRATUS-program. Presented at Proc. 11 Annu. Meet. Soc. Res. Nicotine Tobacco, Prague, Czech Rep.
90. Hall SM, Reus VI, Munoz RF, Sees KL, Humfleet G, et al. 1998. Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch. Gen. Psychiatry 55:683-90
91. Prochazka AV, Weaver MJ, Keller RT, Fryer GE, Licari PA, Lofaso D. 1998. A randomized trial of nortriptyline for smoking cessation. Arch. Intern. Med. 158:2035-39
92. da Costa CL, Younes RN, Lourenco MT. 2002. Stopping smoking: a prospective, randomized, double-blind study comparing nortriptyline to placebo. Chest 122:403-8
93. Hall SM, Humfleet GL, Reus VI, Munoz RF, Hartz DT, Maude-Griffin R. 2002. Psychological intervention and antidepressant treatment in smoking cessation. Arch. Gen. Psychiatry 59:930-36
94. Hughes JR, Stead LF, Lancaster T. 2005. Nortriptyline for smoking cessation: a review. Nicotine Tob. Res. 7:491-99
95. Gossop M. 1988. Clonidine and the treatment of the opiate withdrawal syndrome. Drug Alcohol. Depend. 21:253-59
96. Manhem P, Nilsson LH, Moberg AL, Wadstein J, Hokfelt B. 1985. Alcohol withdrawal: effects of clonidine treatment on sympathetic activity, the renin-aldosterone system, and clinical symptoms. Alcohol. Clin. Exp. Res. 9:238-43
97. Glassman AH, Jackson WK, Walsh BT, Roose SP, Rosenfeld B. 1984. Cigarette craving, smoking withdrawal, and clonidine. Science 226:864-66
98. Ornish SA, Zisook S, McAdams LA. 1988. Effects of transdermal clonidine treatment on withdrawal symptoms associated with smoking cessation. A randomized, controlled trial. Arch. Intern. Med. 148:2027-31
99. Gourlay SG, Stead LF, Benowitz NL. 2004. Clonidine for smoking cessation. Cochrane Database Syst. Rev. 2:CD000058
100. Shytle RD, Penny E, Silver AA, Goldman J, Sanberg PR. 2002. Mecamylamine (Inversine): an old antihypertensive with new research directions. J. Hum. Hypertens 16:453-57
101. Rose JE, Behm FM, Westman EC, Levin ED, Stein RM, Ripka GV. 1994. Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin. Pharmacol. Ther. 56:86-99
102. Rose JE, Behm FM, Westman EC. 1998. Nicotine-mecamylamine treatment for smoking cessation: the role of precessation therapy. Exp. Clin. Psychopharmacol. 6:331-43
103. Eissenberg T, Griffiths RR, Stitzer ML. 1996. Mecamylamine does not precipitate withdrawal in cigarette smokers. Psychopharmacology 127:328-36
104. Fowler JS, Logan J, Wang GJ, Volkow ND. 2003. Monoamine oxidase and cigarette smoking. Neurotoxicology 24:75-82
105. Berlin I, Said S, Spreux-Varoquaux O, Launay JM, Olivares R, et al. 1995. A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. Clin. Pharmacol. Ther. 58:444-52
106. George TP, Vessicchio JC, Termine A, Jatlow PI, Kosten TR, O'Malley SS. 2003. A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. Biol. Psychiatry 53:136-43
107. Berlin I, Aubin HJ, Pedarriosse AM, Rames A, Lancrenon S, Lagrue G. 2002. Lazabemide, a selective, reversible monoamine oxidase B inhibitor, as an aid to smoking cessation. Addiction 97:1347-54
108. Andreoli M, Tessari M, Pilla M, Valerio E, Hagan JJ, Heidbreder CA. 2003. Selective antagonism at dopamine D3 receptors prevents nicotine-triggered relapse to nicotine-seeking behavior. Neuropsychopharmacology 28:1272-80
109. Barrett AC, Miller JR, Dohrmann JM, Caine SB. 2004. Effects of dopamine indirect agonists and selective D1-like and D2-like agonists and antagonists on cocaine self-administration and food maintained responding in rats. Neuropharmacology 47(Suppl. 1):256-73
110. Di Ciano P, Underwood RJ, Hagan JJ, Everitt BJ. 2003. Attenuation of cue-controlled cocaine-seeking by a selective D3 dopamine receptor antagonist SB-277011-A. Neuropsychopharmacology 28:329-38
111. Le Foll B, Sokoloff P, Stark H, Goldberg SR. 2005. Dopamine D3 receptor ligands block nicotine-induced conditioned place preferences through a mechanism that does not involve discriminative-stimulus or antidepressant-like effects. Neuropsychopharmacology 30:720-30
112. Pilla M, Perachon S, Sautel F, Garrido F, Mann A, et al. 1999. Selective inhibition of cocaine-seeking behavior by a partial dopamine D3 receptor agonist. Nature 400:371-75
113. Duarte C, Lefebvre C, Chaperon F, Hamon M, Thiebot MH. 2003. Effects of a dopamine D3 receptor ligand, BP 897, on acquisition and expression of food-, morphine-, and cocaine-induced conditioned place preference, and food-seeking behavior in rats. Neuropsychopharmacology 28:1903-15
114. Le Foll B, Goldberg SR, Sokoloff P. 2005. The dopamine D3 receptor and drug dependence: effects on reward or beyond? Neuropharmacology 49:525-41
115. Benowitz NL, Jacob P. 1994. Metabolism of nicotine to cotinine studied by a dual stable isotope method. Clin. Pharmacol. Ther. 56:483-93
116. Messina ES, Tyndale RF, Sellers EM. 1997. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J. Pharmacol. Exp. Ther. 282:1608-14
117. Brandange S, Lindblom L. 1979. The enzyme "aldehyde oxidase" is an iminium oxidase. Reaction with nicotine delta 1′(5′) iminium ion. Biochem. Biophys. Res. Commun. 91:991-96
118. Murphy S, Raulinaitis V, Brown KM. 2005. Nicotine 5′-oxidation and methyl oxidation byP450 2A enzymes. Drug Metab. Dispos. 33(8):1166-73
119. Williams DE, Shigenaga MK, Castagnoli NJ. 1990. The role of cytochromes P-450 and flavin-containing monooxygenase in the metabolism of (S)-nicotine by rabbit lung. Drug Metab. Dispos. 18:418-28
120. Yamazaki H, Inoue K, Hashimoto M, Shimada T. 1999. Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch. Toxicol. 73:65-70
121. Nakajima M, Yamamoto T, Nunoya K, Yokoi T, Nagashima K, et al. 1996. Role of human cytochrome P4502 A6 in C-oxidation of nicotine. Drug Metab. Dispos. 24:1212-17
122. Cashman JR, Park SB, Yang ZC, Wrighton SA, Jacob P, Benowitz NL. 1992. Metabolism of nicotine by human liver microsomes: stereoselective formation of trans-nicotine N′-oxide. Chem. Res. Toxicol. 5:639-46
123. Park SB, Jacob P, Benowitz NL, Cashman JR. 1993. Stereoselective metabolism of (S)-(-)-nicotine in humans: formation of trans-(S)-(-)-nicotine N-1′-oxide. Chem. Res. Toxicol. 6:880-88
124. Kuehl GE, Murphy SE. 2003. N-glucuronidation of nicotine and cotinine by human liver microsomes and heterologously expressed UDP- glucuronosyltransferases. Drug Metab. Dispos. 31:1361-68
125. Nakajima M, Yamamoto T, Nunoya K, Yokoi T, Nagashima K, et al. 1996. Characterization of CYP2A6 involved in 3′-hydroxylation of cotinine in human liver microsomes. J. Pharmacol. Exp. Ther. 277:1010-15
126. Yamanaka H, Nakajima M, Nishimura K, Yoshida R, Fukami T, et al. 2004. Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted. Eur. J. Pharm. Sci. 22:419-25
127. Lerman C, Tyndale R, Patterson F, Wileyto EP, Shields PG, et al. 2006. Nicotine metabolite ratio predicts the efficacy of transdermal nicotine for smoking cessation. Clin. Pharmacol. Ther. 79:600-8
128. Malaiyandi V, Lerman C, Benowitz NL, Jepson C, Patterson F, Tyndale RF. 2006. Impact of CYP2A6 genotype on pretreatment smoking behavior and nicotine levels from and usage of nicotine replacement therapy. Mol. Psychiatry 11(4):400-9
129. Nakajima M, Kwon JT, Tanaka N, Zenta T, Yamamoto Y, et al. 2001. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans. Clin. Pharmacol. Ther. 69:72-78
130. Oscarson M, McLellan RA, Gullsten H, Yue QY, Lang MA, et al. 1999. Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Lett. 448:105-10
131. Dempsey D, Tutka P, Jacob P, Allen F, Schoedel K, et al. 2004. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin. Pharmacol. Ther. 76:64-72
132. Rao Y, Hoffmann E, Zia M, Bodin L, Zeman M, et al. 2000. Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. Mol. Pharmacol. 58:747-55
133. Schoedel KA, Hoffmann EB, Rao Y, Sellers EM, Tyndale RF. 2004. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics 14:615-26
134. Gu DF, Hinks LJ, Morton NE, Day IN. 2000. The use of long PCR to confirm three common alleles at the CYP2A6 locus and the relationship between genotype and smoking habit. Ann. Hum. Genet. 64:383-90
135. Draper AJ, Madan A, Parkinson A. 1997. Inhibition of coumarin 7-hydroxylase activity in human liver microsomes. Arch. Biochem. Biophys. 341:47-61
136. Koenigs LL, Peter RM, Thompson SJ, Rettie AE, Trager WF. 1997. Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen. Drug Metab. Dispos. 25:1407-15
137. Maenpaa J, Juvonen R, Raunio H, Rautio A, Pelkonen O. 1994. Metabolic interactions of methoxsalen and coumarin in humans and mice. Biochem. Pharmacol. 48:1363-69
138. Zhang W, Kilicarslan T, Tyndale RF, Sellers EM. 2001. Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro. Drug Metab. Dispos. 29:897-902
139. Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, et al. 1993. Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J. Pharmacol. Exp. Ther. 265:401-7
140. Zhang W, Kilicarslan T, Tyndale RF, Seller EM. 2000. Indentification of selective and specific inhibitors of CYP2A6. Clin. Pharmacol. Ther. 67:166 (Abstr.)
141. Taavitsainen P, Juvonen R, Pelkonen O. 2001. In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene. Drug Metab. Dispos. 29:217-22
142. Benowitz NL, Jacob P, Savanapridi C. 1987. Determinants of nicotine intake while chewing nicotine polacrilex gum. Clin. Pharmacol. Ther. 41:467-73
143. Benowitz NL, Jacob P, Denaro C, Jenkins R. 1991. Stable isotope studies of nicotine kinetics and bioavailability. Clin. Pharmacol. Ther. 49:270-77
144. Sellers EM, Dortok D, Tyndale RF. 2002. CYP2A6 inhibition increases plasma nicotine concentrations during nicotine patch and gum. Clin. Pharmacol. Ther. 71:17
145. Tyndale RF, Li Y, Kaplan HL, Seller EM. 1999. Inhibition of nicotine's metabolism: a potential new treatment for tobacco dependence. Clin. Pharmacol. Ther. 65:145 (Abstr.)
146. Sellers EM, Kaplan HL, Tyndale RF. 2000. Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking. Clin. Pharmacol. Ther. 68:35-43
147. Maser E, Richter E, Friebertshauser J. 1996. The identification of 11 beta-hydroxysteroid dehydrogenase as carbonyl reductase of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Eur. J. Biochem. 238:484-89
148. Hecht SS, Trushin N, Reid-Quinn CA, Burak ES, Jones AB, et al. 1993. Metabolism of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3- pyridyl)-1-butanone in the patas monkey: pharmacokinetics and characterization of glucuronide metabolites. Carcinogenesis 14:229-36
149. Hecht SS, Spratt TE, Trushin N. 1988. Evidence for 4-(3-pyridyl)-4- oxobutylation of DNA in F344 rats treated with the tobacco-specific nitrosamines 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and N′-nitrosonornicotine. Carcinogenesis 9:161-65
150. Peterson LA, Carmella SG, Hecht SS. 1990. Investigations of metabolic precursors to hemoglobin and DNA adducts of 4-(methylnitrosamino)-1-(3-pyridyl)- 1-butanone. Carcinogenesis 11:1329-33
151. Nishikawa A, Mori Y, Lee IS, Tanaka T, Hirose M. 2004. Cigarette smoking, metabolic activation and carcinogenesis. Curr. Drug Metab. 5:363-73
152. Fujieda M, Yamazaki H, Saito T, Kiyotani K, Gyamfi MA, et al. 2004. Evaluation of CYP2 A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers. Carcinogenesis 25:2451-58
153. Hecht SS, Chen CB, Hirota N, Ornaf RM, Tso TC, Hoffmann D. 1978. Tobacco-specific nitrosamines: formation from nicotine in vitro and during tobacco curing and carcinogenicity in strain A mice. J Natl. Cancer Inst. 60:819-24
154. Hecht SS, Isaacs S, Trushin N. 1994. Lung tumor induction in A/J mice by the tobacco smoke carcinogens 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and benzo[a]pyrene: a potentially useful model for evaluation of chemopreventive agents. Carcinogenesis 15:2721-25
155. Okubo C, Morishita Y, Minami Y, Ishiyama T, Kano J, et al. 2005. Phenotypic characteristics of mouse lung adenoma induced by 4- (methylnitrosamino)-1-(3-pyridyl)-1-butanone. Mol Carcinog 42:121-26
156. Miyazaki M, Yamazaki H, Takeuchi H, Saoo K, Yokohira M, et al. 2005. Mechanisms of chemopreventive effects of 8-methoxypsoralen against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung adenomas. Carcinogenesis 26:1947-55
157. Tikeuchi H, Saoo K, Yokohira M, Ikeda M, Maeta H, et al. 2003. Pretreatment with 8-methoxypsoralen, a potent human CYP2A6 inhibitor, strongly inhibits lung tumorigenesis induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone in female A/J mice. Cancer Res. 63:7581-83
158. Sellers EM, Ramamoorthy Y, Zeman MV, Djordjevic MV, Tyndale RF. 2003. The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone (NNK) metabolism in vivo. Nicotine Tob. Res. 5:891-99
159. Poso A, Gynther J, Juvonen R. 2001. A comparative molecular field analysis of cytochrome P450 2A5 and 2A6 inhibitors. J. Comput. Aided. Mol. Des. 15:195-202
160. Rahnasto M, Raunio H, Poso A, Wittekindt C, Juvonen RO. 2005. Quantitative structure-activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme. J. Med. Chem. 48:440-49
161. Yano JK, Hsu MH, Griffin KJ, Stout CD, Johnson EF. 2005. Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen. Nat. Struct. Mol. Biol. 12:822-23
162. Asikainen A, Tarhanen J, Poso A, Pasanen M, Alhava E, Juvonen RO. 2003. Predictive value of comparative molecular field analysis modelling of naphthalene inhibition of human CYP2A6 and mouse CYP2A5 enzymes. Toxicol. In Vitro 17:449-55
163. Denton TT, Zhang X, Cashman JR. 2004. Nicotine-related alkaloids and metabolites as inhibitors of human cytochrome P-450 2A6. Biochem. Pharmacol. 67:751-56
164. Fujita K, Kamataki T. 2001. Screening of organosulfur compounds as inhibitors of human CYP2A6. Drug Metab. Dispos. 29:983-89
165. Denton TT, Zhang X, Cashman JR. 2005. 5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6. J. Med. Chem. 48:224-39
166. Nakayama H, Okuda H, Nakashima T, Imaoka S, Funae Y. 1993. Nicotine metabolism by rat hepatic cytochrome P450s. Biochem. Pharmacol. 45:2554-56
167. Schoedel KA, Tyndale RF. 2003. Induction of nicotine-metabolizing CYP2B1
168. Katoh M, Matsui T, Nakajima M, Tateno C, Kataoka M, et al. 2004. Expression of human cytochromes P450 in chimeric mice with humanized liver. Drug Metab. Dispos. 32:1402-10
169. Katoh M, Matsui T, Okumura H, Nakajima M, Nishimura M, et al. 2005. Expression of human phase II enzymes in chimeric mice with humanized liver. Drug Metab. Dispos. 33:1333-40
170. Nishimura M, Yoshitsugu H, Yokoi T, Tateno C, Kataoka M, et al. 2005. Evaluation of mRNA expression of human drug-metabolizing enzymes and transporters in chimeric mouse with humanized liver. Xenobiotica 35:877-90
171. Tateno C, Yoshizane Y, Saito N, Kataoka M, Utoh R, et al. 2004. Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am. J. Pathol. 165:901-12
172. Rose JE. 2006. Nicotine and nonnicotine factors in cigarette addiction. Psychopharmacology 184(3-4):274-85
173. Rose JE, Behm FM, Westman EC, Bates JE, Salley A. 2003. Pharmacologic and sensorimotor components of satiation in cigarette smoking. Pharmacol. Biochem. Behav. 76:243-50
174. Rose JE, Behm FM, Westman EC, Johnson M. 2000. Dissociating nicotine and nonnicotine components of cigarette smoking. Pharmacol. Biochem. Behav. 67:71-81
175. Rose JE, Tashkin DP, Ertle A, Zinser MC, Lafer R. 1985. Sensory blockade of smoking satisfaction. Pharmacol. Biochem. Behav. 23:289-93
176. Rose JE, Zinser MC, Tashkin DP, Newcomb R, Ertle A. 1984. Subjective response to cigarette smoking following airway anesthetization. Addict. Behav. 9:211-15
177. Perkins KA, Gerlach D, Vender J, Grobe J, Meeker J, Hutchison S. 2001. Sex differences in the subjective and reinforcing effects of visual and olfactory cigarette smoke stimuli. Nicotine Tob. Res. 3:141-50
178. Balfour DJ, Fagerstrom KO. 1996. Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disorders. Pharmacol. Ther. 72:51-81
179. Behm FM, Levin ED, Lee YK, Rose JE. 1990. Low-nicotine regenerated smoke aerosol reduces desire for cigarettes. J. Subst. Abuse 2:237-47
180. Behm FM, Schur C, Levin ED, Tashkin DP, Rose JE. 1993. Clinical evaluation of a citric acid inhaler for smoking cessation. Drug Alcohol. Depend. 31:131-38
181. Lancaster T, Stead LF. 2005. Individual behavioural counseling for smoking cessation. Cochrane Database Syst. Rev. 2:CD001292
182. Stead LF, Lancaster T. 2005. Group behavior therapy programmes for smoking cessation. Cochrane Database Syst. Rev. 2:CD001007
183. Hajek P, Stead LF, West R, Jarvis M. 2005. Relapse prevention interventions for smoking cessation. Cochrane Database Syst. Rev. 1:CD003999